Trial Profile

A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination with Pretomanid and Linezolid in Adult Participants with Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linezolid (Primary) ; Pretomanid (Primary) ; TBAJ-876 (Primary) ; Bedaquiline; Isoniazid/rifampicin; Rifampicin/isoniazid/pyrazinamide/ethambutol
Indications Pulmonary tuberculosis
Focus Therapeutic Use
Sponsors Global Alliance for TB Drug Development

19 Sep 2024 Planned primary completion date changed from 1 Feb 2025 to 1 Jan 2025.
19 Sep 2024 Status changed from recruiting to active, no longer recruiting.
05 Mar 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com